Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Opthea Limited Sponsored ADR ( (OPT) ) is now available.
Opthea Limited announced the completion of the final week 52 patient visit for its COAST Phase 3 trial, which evaluates the combination of sozinibercept with aflibercept for treating wet AMD. This milestone is significant for the company as it anticipates releasing topline results in early Q2 2025, which could strengthen its market position if successful, potentially allowing sozinibercept to be used broadly with anti-VEGF-A therapies.
More about Opthea Limited Sponsored ADR
Opthea Limited is a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal diseases such as wet age-related macular degeneration (wet AMD) and diabetic macular edema. Opthea’s lead product, sozinibercept, is being tested in pivotal Phase 3 clinical trials to improve visual outcomes in combination with anti-VEGF-A therapies.
YTD Price Performance: 41.38%
Average Trading Volume: 24,719
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $796.5M
See more insights into OPT stock on TipRanks’ Stock Analysis page.
